Handelsavisen
prelaunch
Companies ›Healthcare ›LYKA.NS
LY
LYKA.NS — NSE (India) Pharmaceuticals

Lyka.Ns

$61,62
Open in Charts → Attach watcher ⌖
— —
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
—
P/E
—
EV / Rev
—
Div yield
—
Op margin
8,1 %
ROE
7,7 %
Net margin
5,8 %
Debt / equity
0,38
Beta
—
52w range
—
Volume
—
Day range
—
Prev close
—
Open
—
Next earnings
—
Ex-dividend
—
TR 1Y
—
About

Lyka operates in the pharmaceuticals industry, focusing on the development, manufacturing, and distribution of prescription and over-the-counter medications.

Business. Lyka operates in the pharmaceuticals industry, focusing on the development, manufacturing, and distribution of prescription and over-the-counter medications.

Classification92 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
IndustryPharmaceuticals
Generated · model-assisted
Sell-side consensus
—consensus pending
— buy— hold— sell
Avg 12m price target—
Upcoming events
— missing data
See all catalysts →

At a glance

Score
—
not yet scored
Valuation
—
valuation pending
Analysts
—
not yet wired
Ownership
—
not yet wired
Profitability→
7,7 %
return on equity
Quality
—
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning LYKA.

    • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to LYKA.NS. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    Lyka operates in the pharmaceuticals industry, focusing on the development, manufacturing, and distribution of prescription and over-the-counter medications.

    Classification92 %
    SectorHealthcare
    Business sectorPharmaceuticals & Medical Research
    IndustryPharmaceuticals
    AI synthesis
    GENERATED

    Lyka's capital structure shows a debt-to-equity ratio of 0.38, indicating a relatively conservative leverage position compared to the industry median of 0.55. The company's liquidity is assessed as medium, with a current ratio of 1.45, which is below the industry median of 1.80. Free cash flow is negative at -9.52 million INR, while operating cash flow is positive at 18.99 million INR.

    Profitability metrics show a return on equity (ROE) of 7.74%, which is below the industry median of 12.30%. Return on assets (ROA) is at 4.55%, also below the median of 6.80%. The company's net income of 80.12 million INR is supported by a gross profit margin of 56.75%, which is in line with the industry median of 57.20%.

    Lyka's revenue is concentrated in a single business segment, with no disclosed geographic diversification. The company's revenue is entirely attributed to domestic operations, indicating a high concentration risk in the Indian market.

    Growth trajectory for the current fiscal year is projected to be flat, with a revenue delta of 0.00% year-over-year. The outlook for the next fiscal year is also neutral, with a projected revenue delta of 0.00%.

    Risk factors include medium liquidity risk due to a current ratio below the industry median and a negative net cash position after subtracting total debt. Dilution risk is assessed as low, with no dilution potential identified in the basic shares outstanding.

    Recent events include the filing of the latest financial report, which disclosed the company's financial position and operational performance. No significant earnings call transcripts or regulatory filings have been released in the past quarter.

    Key takeaways
    • Lyka maintains a conservative debt-to-equity ratio of 0.38, below the industry median of 0.55.
    • The company's ROE of 7.74% is below the industry median of 12.30%, indicating suboptimal capital efficiency.
    • Revenue is entirely concentrated in domestic operations, exposing the company to regional economic risks.
    • Growth projections for the next two fiscal years are flat, with no significant revenue expansion expected.
    • Liquidity risk is moderate, with a current ratio of 1.45 and negative net cash after debt.

    Bull / Bear case

    analysis pipeline
    — missing data

    In focus — financials by report

    Valuation

    Market price
    $61,62
    Market cap
    —
    Enterprise valueⓘ
    —
    P/Eⓘ
    —
    Non-GAAP P/Eⓘ
    —
    EV / Revenueⓘ
    —
    EV / Op incomeⓘ
    —
    EV / OCFⓘ
    —
    P / Bⓘ
    —
    P / Tangible bookⓘ
    —
    Tangible book
    $1.04B
    Net cashⓘ
    -$392.5M
    Current ratioⓘ
    1.4
    Debt / equityⓘ
    0.4
    ROAⓘ
    4.5%
    ROEⓘ
    7.7%
    Cash conversionⓘ
    24.0%
    CapEx / revenueⓘ
    -11.3%
    SBC / revenueⓘ
    —
    Dilution ratioⓘ
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin8,1 %Above median
    Net Margin5,8 %Above median
    ROE7,7 %Above median
    Capex / Rev-11,3 %Below median
    D/E0,38Below median
    Cash Conv0,24Bottom quartile

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Capex To Revenue
      capital_expenditure / revenue
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    Source documents
    • LYKA.NS Market data — financials · 2026-05-28

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    LYKA.NSCanonical
    NSE (India) · USD

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    — missing data
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage